Brought to you by 
Cubist licenses antibacterial Cidecin to Gilead
11 Sep 2002
Executive Summary
Cubist Pharmaceuticals (anti-infectives) has licensed Gilead Sciences (also infectious disease therapeutics) exclusive rights in 16 European countries to both injectable and oral forms of its Cidecin (daptomycin), once approved.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
Biotechnology
- Large Molecule
Deal Status
- Terminated
Deal Type
-
Alliance
- Includes Contract
- Intra-Biotech Deal
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cubist licenses antibacterial Cidecin to Gilead
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice